Skip to main content

Table 1 Patient characteristic (N = 77)

From: Effect of dose rate on pulmonary toxicity in patients with hematolymphoid malignancies undergoing total body irradiation

 

Dose rate < 6 cGy/min (N = 23)

Dose rate ≥ 6 cGy/min (N = 54)

P-value

Age at TBI (year)

29.4 ± 18.6 (1.9–66.4)

15.9 ± 8.9 (1.8–41.7)

0.002b

Sex

 Male

14 (60.9%)

32 (59.9%)

0.895a

 Female

9 (39.1%)

22 (40.1%)

 

Type of Cancer

 ALL

15 (65.2%)

32 (59.3%)

0.172a

 AML

2 (8.7%)

14 (25.9%)

 

 Others

6 (26.1%)

8 (14.8%)

 

Total dose (Gy)

11.7 ± 0.9 (9–12)

10.9 ± 1.1 (9–12)

0.004b

Daily dose (Gy)

3.0 ± 0.1 (2.5–3.0)

3.1 ± 0.2 (2.3–3.3)

0.001b

 Daily dose < 3

1 (4.3%)

2 (3.7%)

 

 Daily dose ≥3

22 (95.7%)

52 (96.3%)

0.017a

Donor type

 Related

16 (69.6%)

22 (40.7%)

0.021a

 Unrelated

7 (30.4%)

32 (59.3%)

 

Conditioning regimen

 Cyclophosphamide

4 (17.4%)

8 (14.8%)

0.271a

 Cyclophosphamide + otherc

14 (60.9%)

24 (44.4%)

 

 Othersd

5 (21.7%)

22 (40.7%)

 

Number of prior chemotherapy regimens

 1

3 (13.0%)

14 (25.9%)

0.193a

 2

8 (34.8%)

23 (42.6%)

 

  ≥ 3

12 (52.2%)

17 (31.5%)

 
  1. aP-value by chi-square test. bP-value by Mann-Whitney U test
  2. c Other: cytarabine, fludarabine, etoposide
  3. d Others: cytarabine/fludaraibine, busulfan/fludarabine/etoposide, melphalan, melphalan/fludarabine, thiotepa